“Gilead (GILD) has been reiterated by TheStreet Ratings as a buy with a ratings score of A . The company’s strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, increase in net income, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.”
,” the firm’s analyst commented.
Several other analysts have also recently commented on the stock. Analysts at RBC Capital raised their price target on shares of Gilead Sciences from $44.00 to $50.00 in a research note to investors on Thursday, February 28th. They now have an outperform rating on the stock. Separately, analysts at Credit Suisse reiterated an outperform rating on shares of Gilead Sciences in a research note to investors on Wednesday, February 27th. They now have a $55.00 price target on the stock. Finally, analysts at Bank of America reiterated a buy rating on shares of Gilead Sciences in a research note to investors on Monday, February 25th.
Twenty-one research analysts have rated the stock with a buy rating, three have issued an overweight rating, and six have assigned a hold rating to the company’s stock. Gilead Sciences currently has an average rating of overweight and an average price target of $47.50.
Shares of Gilead Sciences traded up 2.58% during mid-day trading on Friday, hitting $45.00. Gilead Sciences has a one year low of $22.40 and a one year high of $43.88. The stock’s 50-day moving average is currently $40.64. The company has a market cap of $68.362 billion and a P/E ratio of 26.75.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.